trans-Hexahydroisobenzofuran-1,3-dione

We are trans-Hexahydroisobenzofuran-1,3-dione CAS:71749-03-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  trans-Hexahydroisobenzofuran-1,3-dione
CAS.NO: 71749-03-6
Synonyms:
(3aR,7aR)-3a,4,5,6,7,7a-hexahydro-2-benzofuran-1,3-dione

Molecular Formula:C8H10O3
Molecular Weight:154.16300

Physical and Chemical Properties:
Density: 1.2±0.1 g/cm3
Boiling point: 283.4±0.0 °C at 760 mmHg
Melting point: 165ºC
Flash point:143.9±16.5 °C
Refractive index: 1.502

Specification:
Appearance:  powder
Purity:≥98%
Moisture:0.5%Max.

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Lurasidone hydrochloride CAS:367514-88-3
Intermediates of Lurasidone CAS:367514-87-2

Related News: The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this.542-58-5 Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.2-bromo-6-fluorobenzaldehído CAS:360575-28-6 Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.4-Bromophenylboronic acid CAS:5467-74-3 With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.